Exec Chat: Catching Up With Drug-Device Developers Sequana At LSX
Executive Summary
The company’s dual drug-device development pipeline is progressing well, with the company expecting its device, the Alfapump, to hit US clinics in 2025.
Topics
- Originals
- Exec Chats
- Subjects
- Clinical Trials
- Platform Technologies
- Deals
- Therapy Areas
- Cardiovascular
- Industries
- Medical Device
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MT147921
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
MT147921
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.